Citigroup โคPredictsโค Significant gains for Amylyx Pharmaceuticals (NASDAQ:AMLX)
NEW YORK, NY – Citigroup analysts issued a bullish forecast for Amylyx pharmaceuticals (NASDAQ:AMLX), anticipating ample price recognition for the biotechnology company’s stock. The firm’s optimism followsโ increased investment from several prominent institutional investors and hedge โฃfunds.
Recent filings reveal significant stake increases in Amylyx Pharmaceuticals duringโค the second and firstโ quartersโ of 2023. Adage Capital Partners GP L.L.C.โค boosted itsโค holdings by 54.5%,โค now owning 8,800,000 shares valued at โค$56,408,000, after acquiring an additional 3,102,395 shares. Perceptive Advisors LLC increased its position byโฃ 0.4%, โขholdingโ 7,902,365 shares worth โ$50,654,000, with a purchase of 28,017 shares. Saturn V Capital Managementโข LP lifted its stakeโ by 34.4% to 3,260,570โฃ shares โฃ($20,900,000), adding 834,134 โขshares.
Millennium Management LLC saw the largest percentage increase, a โค418.6% jump in the first quarter, now โowning 3,081,853 shares ($10,910,000) after buying 2,487,617 shares.Nantahala Capital Managementโ LLC increased its stake by 102.1% in โthe first quarter, now holding 2,934,405โ shares ($10,388,000)โ following the purchase โคof 1,482,252 shares.
Currently, institutional investors and hedge fundsโ collectively ownโฃ 95.84% of Amylyx Pharmaceuticals’ stock.
Amylyx โคPharmaceuticals is a โcommercial-stage biotechnology company focused on the discovery and development of treatments for amyotrophic lateral sclerosisโ (ALS) and other neurodegenerative diseases. Its key product, RELYVRIO (sodium phenylbutyrate and taurursodiol), is approvedโ inโค the Unitedโ states for the treatmentโฃ of ALS in adults and is marketed as ALBRIOZA in Canada for the same indication.
